계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Sera Prognostics
About
Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $40M
- Industries
- Biotechnology,Health Care,Hospital,Medical,Medical Device
- Founded date
- Jan 1, 2008
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 23, 2017 | Series C | $22.73M | 1 |
LabCorp
|
— | Detail |
| Jan 10, 2017 | Series C | $40M | 1 |
LabCorp
|
— | Detail |
| Jan 7, 2015 | Series B | $20M | 1 | — | — | Detail |
| Nov 18, 2014 | Series B | $5M | 1 | — | — | Detail |
| Nov 15, 2011 | Series A | $19.30M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
LabCorp
|
Yes | Series C |
Upstart Life Ventures
|
— | Series B |
Upstart Capital
|
— | Series A |
